Advertisement

Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: An analysis of surgical morbidity and mortality

      Background

      To date, reported surgical morbidity and mortality for pleurectomy/decortication and extrapleural pneumonectomy performed for malignant pleural mesothelioma primarily represent the experience of a few specialized centers. For comparison, we examined early outcomes of pleurectomy/decortication and extrapleural pneumonectomy from a broader group of centers/surgeons participating in the Society of Thoracic Surgeons-General Thoracic Database.

      Methods

      All patients in the Society of Thoracic Surgeons-General Thoracic Database (version 2.081, representing 2009-2011) who underwent pleurectomy/decortication or extrapleural pneumonectomy for malignant pleural mesothelioma were identified. Patient characteristics, morbidity, mortality, center volume, and procedure were examined using univariable and multivariable analyses.

      Results

      A total of 225 patients underwent pleurectomy/decortication (n = 130) or extrapleural pneumonectomy (n = 95) for malignant pleural mesothelioma at 48 centers. Higher volumes of procedures (≥5/y) were performed at 3 pleurectomy/decortication and 2 extrapleural pneumonectomy centers. Patient characteristics were statistically equivalent between pleurectomy/decortication and extrapleural pneumonectomy groups, except those undergoing extrapleural pneumonectomy were younger (63.2 ± 7.8 years vs 68.3 ± 9.5 years; P < .001) and more likely to have received preoperative chemotherapy (30.1% vs 17.8%; P = .036). Major morbidity was greater after extrapleural pneumonectomy, including acute respiratory distress syndrome (8.4% vs 0.8%; P = .005), reintubation (14.7% vs 2.3%; P = .001), unexpected reoperation (9.5% vs 1.5%; P = .01), and sepsis (4.2% vs 0%; P = .03), as was mortality (10.5% vs 3.1%; P = .03). Multivariate analyses revealed that extrapleural pneumonectomy was an independent predictor of major morbidity or mortality (odds ratio, 6.51; P = .001). Compared with high-volume centers, increased acute respiratory distress syndrome was seen in low-volume centers performing extrapleural pneumonectomy (0% vs 12.5%; P = .05).

      Conclusions

      Extrapleural pneumonectomy is associated with greater morbidity and mortality compared with pleurectomy/decortication when performed by participating surgeons of the Society of Thoracic Surgeons-General Thoracic Database. Effects of center volume require further study.

      CTSNet classification

      Abbreviations and Acronyms:

      ARDS (acute respiratory distress syndrome), EPP (extrapleural pneumonectomy), MPM (malignant pleural mesothelioma), PD (pleurectomy/decortication), STS-GTD (Society of Thoracic Surgeons-General Thoracic Database)
      To read this article in full you will need to make a payment

      References

        • Merritt N.
        • Blewett C.J.
        • Miller J.D.
        • Bennett W.F.
        • Young J.E.
        • Urschel J.D.
        Survival after conservative (palliative) management of pleural malignant mesothelioma.
        J Surg Oncol. 2001; 78: 171-174
        • Vogelzang N.J.
        • Rusthoven J.J.
        • Symanowski J.
        • Denham C.
        • Kaukel E.
        • Ruffie P.
        • et al.
        Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
        J Clin Oncol. 2003; 21: 2636-2644
        • Rusch V.
        • Baldini E.H.
        • Bueno R.
        • De Perrot M.
        • Flores R.
        • Hasegawa S.
        • et al.
        The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: Meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass.
        J Thorac Cardiovasc Surg. 2013; 145: 909-910
        • Park E.K.
        • Takahashi K.
        • Hoshuyama T.
        • Cheng T.J.
        • Delgermaa V.
        • Le G.V.
        • et al.
        Global magnitude of reported and unreported mesothelioma.
        Environ Health Perspect. 2011; 119: 514-518
        • Delgermaa V.
        • Takahashi K.
        • Park E.K.
        • Le G.V.
        • Hara T.
        • Sorahan T.
        Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008.
        Bull World Health Organ. 2011; 89: 716-724
        • Flores R.M.
        • Pass H.I.
        • Seshan V.E.
        • Dycoco J.
        • Zakowski M.
        • Carbone M.
        • et al.
        Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
        J Thorac Cardiovasc Surg. 2008; 135: 620-626
        • Rusch V.W.
        • Giroux D.
        • Kennedy C.
        • Ruffini E.
        • Cangir A.K.
        • Rice D.
        • et al.
        Initial analysis of the international association for the study of lung cancer mesothelioma database.
        J Thorac Oncol. 2012; 7: 1631-1639
        • Treasure T.
        • Lang-Lazdunski L.
        • Waller D.
        • Bliss J.M.
        • Tan C.
        • Entwisle J.
        • et al.
        Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.
        Lancet Oncol. 2011; 12: 763-772
        • Weder W.
        • Stahel R.A.
        • Baas P.
        • Dafni U.
        • de Perrot M.
        • McCaughan B.C.
        • et al.
        The MARS feasibility trial: conclusions not supported by data.
        Lancet Oncol. 2011; 12: 1093-1094
        • Bliss J.M.
        • Coombes G.
        • Darlison L.
        • Edwards J.
        • Entwisle J.
        • Kilburn L.
        • et al.
        The MARS feasibility trial: conclusions not supported by data – Authors’ reply.
        Lancet Oncol. 2011; 12: 1094-1095
        • Cao C.Q.
        • Yan T.D.
        • Bannon P.G.
        • McCaughan B.C.
        A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma.
        J Thorac Oncol. 2010; 5: 1692-1703
        • Teh E.
        • Fiorentino F.
        • Tan C.
        • Treasure T.
        A systematic review of lung-sparing extirpative surgery for pleural mesothelioma.
        J R Soc Med. 2011; 104: 69-80
        • Weder W.
        • Stahel R.A.
        • Bernhard J.
        • Bodis S.
        • Vogt P.
        • Ballabeni P.
        • et al.
        • Swiss Group for Clinical Cancer Research
        Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
        Ann Oncol. 2007; 18: 1196-1202
        • Krug L.M.
        • Pass H.I.
        • Rusch V.W.
        • Kindler H.L.
        • Sugarbaker D.J.
        • Rosenzweig K.E.
        • et al.
        Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
        J Clin Oncol. 2009; 27: 3007-3013
        • Sugarbaker D.J.
        • Flores R.M.
        • Jaklitsch M.T.
        • Richards W.G.
        • Strauss G.M.
        • Corson J.M.
        • et al.
        Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
        J Thorac Cardiovasc Surg. 1999; 117: 54-63
        • Hiddinga B.I.
        • van Meerbeeck J.P.
        Surgery in mesothelioma - where do we go after Mars?.
        J Thorac Oncol. 2013; 8: 525-529

      Linked Article